Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors

被引:26
|
作者
Lu, Yipin [1 ]
Knapp, Mark [1 ]
Crawford, Kenneth [2 ]
Warne, Robert [2 ]
Elling, Robert [1 ]
Yan, Kelly [2 ]
Doyle, Michael [2 ]
Pardee, Gwynn [2 ]
Zhang, Li [2 ]
Ma, Sylvia [2 ]
Mamo, Mulugeta [1 ]
Ornelas, Elizabeth [1 ]
Pan, Yue [1 ]
Bussiere, Dirksen [1 ]
Jansen, Johanna [1 ]
Zaror, Isabel [2 ]
Lai, Albert [2 ]
Barsanti, Paul [1 ]
Sim, Janet [2 ]
机构
[1] Novartis Inst Biomed Res, Global Discovery Chem, Emeryville, CA 94608 USA
[2] Novartis Inst Biomed Res, Oncol, Emeryville, CA 94608 USA
关键词
ATR; PI3K alpha; mutant; crystal structure; ATR inhibitor; PROTEIN-KINASE-A; CELL-CYCLE; CANCER-CELLS; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; DISCOVERY; POTENT; THERAPY; IDENTIFICATION; DETERMINANTS;
D O I
10.1016/j.jmb.2017.04.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ATR, a protein kinase in the PIKK family, plays a critical role in the cell DNA-damage response and is an attractive anticancer drug target. Several potent and selective inhibitors of ATR have been reported showing significant antitumor efficacy, with most advanced ones entering clinical trials. However, due to the absence of an experimental ATR structure, the determinants contributing to ATR inhibitors' potency and specificity are not well understood. Here we present the mutations in the ATP-binding site of PI3K alpha to progressively transform the pocket to mimic that of ATR. The generated PI3K alpha mutants exhibit significantly improved affinity for selective ATR inhibitors in multiple chemical classes. Furthermore, we obtained the X-ray structures of the PI3K alpha mutants in complex with the ATR inhibitors. The crystal structures together with the analysis on the inhibitor affinity profile elucidate the roles of individual amino acid residues in the binding of ATR inhibitors, offering key insights for the binding mechanism and revealing the structure features important for the specificity of ATR inhibitors. The ability to obtain structural and binding data for these PI3K alpha mutants, together with their ATR-like inhibitor binding profiles, makes these chimeric PI3K alpha proteins valuable model systems for structure-based inhibitor design. (C) 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecomnnons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1684 / 1704
页数:21
相关论文
共 43 条
  • [21] Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT)
    Yang, Hongfang
    Medeiros, Patricia F.
    Raha, Kaushik
    Elkins, Patricia
    Lind, Kenneth E.
    Lehr, Ruth
    Adams, Nicholas D.
    Burgess, Joelle L.
    Schmidt, Stanley J.
    Knight, Steven D.
    Auger, Kurt R.
    Schaber, Michael D.
    Franklin, G. Joseph
    Ding, Yun
    DeLorey, Jennifer L.
    Centrella, Paolo A.
    Mataruse, Sibongile
    Skinner, Steven R.
    Clark, Matthew A.
    Cuozzo, John W.
    Evindar, Ghotas
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (05): : 531 - 536
  • [22] Systematical Evaluation of the Structure-Cardiotoxicity Relationship of 7-Azaindazole-based PI3K Inhibitors Designed by Bioisosteric Approach
    Tianze Wu
    Yi Chen
    Chengbin Yang
    Mingzhu Lu
    Fang Geng
    Jianhua Guo
    Yan Pi
    Yun Ling
    Jun Xu
    Tong Cai
    Lei Lu
    Yaming Zhou
    Cardiovascular Toxicology, 2023, 23 : 364 - 376
  • [23] Systematical Evaluation of the Structure-Cardiotoxicity Relationship of 7-Azaindazole-based PI3K Inhibitors Designed by Bioisosteric Approach
    Wu, Tianze
    Chen, Yi
    Yang, Chengbin
    Lu, Mingzhu
    Geng, Fang
    Guo, Jianhua
    Pi, Yan
    Ling, Yun
    Xu, Jun
    Cai, Tong
    Lu, Lei
    Zhou, Yaming
    CARDIOVASCULAR TOXICOLOGY, 2023, 23 (11-12) : 364 - 376
  • [24] Selective degradation of mutant PIK3CA promotes increased mutant specificity in a subset of PI3K ATP-competitive inhibitors
    Nguyen, Lan
    Edgar, Kyle
    Song, Kyung
    Schmidt, Stephen
    Schutz, Victorai
    Ishisoko, Noriko
    Torres, Eric
    Das, Akash
    Murali, Divya
    Sideris, Steve
    Wendorff, Timothy
    Saabye, Matt
    Purkey, Hans
    Sudhamsu, Jawahar
    Staben, Steven
    Hanan, Emily
    Hatzivassiliou, Georgia
    Friedman, Lori
    Endres, Nicholas F.
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 43 - 43
  • [25] ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding
    Gong, Grace Q.
    Masson, Glenn R.
    Lee, Woo-Jeong
    Dickson, James M. J.
    Kendall, Jackie D.
    Rathinaswamy, Manoj K.
    Buchanan, Christina M.
    Middleditch, Martin
    Owen, Brady M.
    Spicer, Julie A.
    Rewcastle, Gordon W.
    Denny, William A.
    Burke, John E.
    Shepherd, Peter R.
    Williams, Roger L.
    Flanagan, Jack U.
    BIOCHEMICAL JOURNAL, 2024, 481 (23) : 1787 - 1802
  • [26] Use of Reverse Phase Protein Arrays to Identify Biomarkers of Response to PI3K/mTOR Inhibitors in Ovarian Cancer Models
    Tashkandi, G.
    Mullen, P.
    Goltsov, A.
    Bown, J. L.
    Harrison, D. J.
    Langdon, S. P.
    JOURNAL OF PATHOLOGY, 2013, 231 : 25 - 25
  • [27] Association for Academic Surgery Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors
    Gunder, Laura C.
    Moyer, Tyra H.
    Johnson, Hillary R.
    Auyeung, Andrew S.
    Leverson, Glen E.
    Zhang, Wei
    Matkowskyj, Kristina A.
    Carchman, Evie H.
    JOURNAL OF SURGICAL RESEARCH, 2023, 282 : 137 - 146
  • [28] Use of PI3K/mTOR/Akt inhibitors as skin protectors to spare skin from glucocorticoid-induced atrophy
    Agarwal, S.
    Mirzoeva, S.
    Readhead, B.
    Lesovaya, E.
    Dudley, J. T.
    Budunova, I.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S125 - S125
  • [29] Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
    Moore, Nathan F.
    Azarova, Anna M.
    Bhatnagar, Namrata
    Ross, Kenneth N.
    Drake, Lauren E.
    Frumm, Stacey
    Liu, Qinsong S.
    Christie, Amanda L.
    Sanda, Takaomi
    Chesler, Louis
    Kung, Andrew L.
    Gray, Nathanael S.
    Stegmaier, Kimberly
    George, Rani E.
    ONCOTARGET, 2014, 5 (18) : 8737 - 8749
  • [30] Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Fluorinated Candidates as PI3K Inhibitors: Targeting Fluorophilic Binding Sites
    Tantawy, Ahmed H.
    El-Behairy, Mohammed Farrag
    Abd-Allah, Walaa Hamada
    Jiang, Hong
    Wang, Man-Qun
    Marzouk, Adel A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (23) : 17468 - 17485